Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

 v2.3.0.11
Condensed Consolidated Balance Sheets (USD $)
In Thousands
Jun. 30, 2011
Dec. 31, 2010
ASSETS    
Cash and cash equivalents $ 10,597 $ 8,691
Marketable securities 20,897 6,008
Prepaid expenses and other current assets 1,080 944
Total current assets 32,574 15,643
Property and equipment, net 128 271
Restricted cash and other assets 290 290
Total assets 32,992 16,204
LIABILITIES AND STOCKHOLDERS' EQUITY    
Accounts payable 478 252
Accrued clinical and development expenses 2,677 2,439
Accrued liabilities 1,315 823
Total current liabilities 4,470 3,514
Warrant liability 15,689 7,499
Deferred rent 96 248
Total liabilities 20,255 11,261
Commitments and contingencies (Note 6)    
Stockholders' equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding    
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 48,805,008 shares at June 30, 2011 and 33,702,242 shares at December 31, 2010 49 34
Additional paid-in capital 255,418 231,383
Accumulated other comprehensive gain (loss) (2) 1
Deficit accumulated during the development stage (242,728) (226,475)
Total stockholders' equity 12,737 4,943
Total liabilities and stockholders' equity $ 32,992 $ 16,204